Skip to Content

Mesoblast Ltd MEOBF

Morningstar Rating
$0.25 +0.02 (7.81%)
View Full Chart
Unlock Our Analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

MEOBF is trading at a 52% discount.
Price
$0.25
Fair Value
$3.86
Uncertainty
Extreme
1-Star Price
$5.39
5-Star Price
$5.99
Economic Moat
Lszz
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MEOBF is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$0.23
Day Range
$0.250.25
52-Week Range
$0.231.00
Bid/Ask
$0.22 / $0.32
Market Cap
$203.42 Mil
Volume/Avg
420 / 598

Key Statistics

Price/Earnings (Normalized)
Price/Sales
24.63
Dividend Yield
Dividend Yield (Forward)
Total Yield

Company Profile

Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
83

Valuation

Metric
MEOBF
Price/Earnings (Normalized)
Price/Book Value
0.41
Price/Sales
24.63
Price/Cash Flow
Price/Earnings
MEOBF

Financial Strength

Metric
MEOBF
Quick Ratio
1.86
Current Ratio
1.95
Interest Coverage
Quick Ratio
MEOBF

Profitability

Metric
MEOBF
Return on Assets (Normalized)
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
MEOBF

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRNmsq$458.6 Bil
VRTX
Vertex Pharmaceuticals IncFmjhx$90.5 Bil
REGN
Regeneron Pharmaceuticals IncVljxm$88.8 Bil
SGEN
Seagen Inc Ordinary SharesXssqx$40.1 Bil
MRNA
Moderna IncPzty$30.4 Bil
ARGX
argenx SE ADRXcds$27.0 Bil
BNTX
BioNTech SE ADRXxrwp$23.6 Bil
ALNY
Alnylam Pharmaceuticals IncZdfhff$21.5 Bil
BMRN
Biomarin Pharmaceutical IncSqxnsq$17.4 Bil
INCY
Incyte CorpRvjyjt$12.1 Bil